Efforts to eradicate malaria are hampered by the presence of hypnozoites, persisting stages in the liver that can reactivate after prolonged periods of time enabling further transmission and causing renewed disease. Large-scale drug screening is needed to identify compounds with antihypnozoite activity, but current platforms rely on time-consuming high-content fluorescence imaging as read-out, limiting assay throughput. We here report an ultrafast and sensitive dual-luciferase-based method to differentiate hypnozoites from liver stage schizonts using a transgenic parasite line that contains Nanoluc driven by the constitutive promoter, as well as firefly luciferase driven by the schizont-specific promoter. The transgenic parasite line showed similar fitness and drug sensitivity profiles of selected compounds to wild type. We demonstrate robust bioluminescence-based detection of hypnozoites in 96-well and 384-well plate formats, setting the stage for implementation in large scale drug screens.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7203758PMC
http://dx.doi.org/10.1021/acs.analchem.0c00547DOI Listing

Publication Analysis

Top Keywords

transgenic parasite
8
dual-luciferase-based fast
4
fast sensitive
4
sensitive detection
4
detection malaria
4
hypnozoites
4
malaria hypnozoites
4
hypnozoites discovery
4
discovery antirelapse
4
antirelapse compounds
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!